Venetoclax

1:17
CLL14: venetoclax-obinutuzumab improves PFS and MRD in untreated, reduced fitness CLL
Michael Hallek
1:45
What’s to come for MDS therapy?
David Sallman
2:06
Venetoclax and ibrutinib for R/R CLL: analysis from the VIsion/HO141 trial
Arnon Kater
1:28
Venetoclax resistance in CLL
Arnon Kater
2:03
Venetoclax and obinutuzumab combination therapy for CLL
Susan O’Brien
1:07
MCL trials to watch out for at ASH 2019
Simon Rule
1:42
Moving towards chemo-free regimens in CLL
Michael Hallek
1:35
CLL: Venetoclax in combination with obinutuzumab
Tanya Siddiqi
4:47
Liso-Cel in CLL
Tanya Siddiqi
5:51
Major CLL updates from EHA 2019
Patrick Thornton
3:08
Venetoclax-IDH inhibitor combination therapy for AML
Naval Daver
4:09
ADCs for AML: potential alternatives to gemtuzumab ozogamicin
Naval Daver
2:07
ADCs for AML: gemtuzumab ozogamicin
Naval Daver
2:57
Venetoclax and FLT3 inhibitor combination therapy for AML
Naval Daver
4:09
QuANTUM-R: quizartinib looks promising for FLT3-ITD mutated AML
Naval Daver
1:24
Venetoclax plus obinutuzumab in CKT CLL: analysis from the CLL14 trial
Othman Al-Sawaf
VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

VJHO needs the contact information you provide to inform you about our latest hemonc news and videos, educational courses and industry supported content (some of which may be promotional in nature). You may unsubscribe from these communications at anytime. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.

The content of VJHemOnc is intended for healthcare professionals